Drug intelligence / Profile preview

CI-976

Development stage
Preclinical
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

CI-976 is a potent, orally active, and selective small molecule inhibitor of acyl-coenzyme A:cholesterol acyltransferase (ACAT, also known as sterol O-acyltransferase or SOAT), with an IC50 of approximately 73 nM. It blocks cholesterol esterification by inhibiting both ACAT1 and ACAT2 isozymes, and also inhibits lysophospholipid acyltransferase (LPAT) activity at higher concentrations. CI-976 lowers non-HDL cholesterol and increases HDL in animal models of dyslipidemia. Structurally, it is an anilide and lysophospholipid acyltransferase antagonist from the fatty acyl amide analog family. It is used primarily as a tool compound in research settings, not for therapeutic use, and has been widely cited in studies of cholesterol metabolism, lipid droplet biology, and membrane trafficking[1][2][4][5][7][8][9][13][14][15].

Other names
2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide
02

Targets

ACAT1 (Acyl-coenzyme A:cholesterol O-acyltransferase 1)NMBR (Neuromedin B receptor)AGPAT3 (1-acyl-sn-glycerol-3-phosphate acyltransferase 3)SOAT1 (Sterol O-acyltransferase)LPLAT (Lysophospholipid acyltransferase)

Beyond the preview

Go deeper on CI-976.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CI-976.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call